Anticoagulation and Thrombembolism During Bevacizumab Treatment – To Be Careful or Fearful?
Authors:
Š. Tuček; A. Jurečková; J. Tomášek; D. Adámková Krákorová; J. Halámková; L. Pochop
Authors‘ workplace:
Klinika komplexní onkologické péče LF MU a Masarykův onkologický ústav, Brno
Published in:
Klin Onkol 2015; 28(4): 293-295
Category:
Short Communication
doi:
https://doi.org/10.14735/amko2015293
Overview
Inhibition of angiogenesis is a valid approach in today’s medicine. Besides oncology, it is used in ophthalmology, as well. In oncology, angiogenesis inhibition has become a routine and accessible method. A combination of angiogenesis inhibition and other therapies, including anticoagulation and antiaggregation is common in many cases. Bevacizumab is the most used antiangiogenic agent and has been in use for the longest period of time. A concomitant administration of angiogenesis inhibitors and anticoagulation may be feared by oncologists. From the available literature it is obvious that concomitant administration of bevacizumab and anticoagulation is safe. Also, use of antiaggregation and bevacizumab is safe. The risk of venous and arterial thromboembolism is real during the treatment with bevacizumab. Therefore, concomitant anticoagulation is not only possible but also may be desirable.
Key words:
bevacizumab – thromboembolism – antithrombotic agents
This study was supported by MZ ČR – RVO (MOÚ, 00209805).
The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.
The Editorial Board declares that the manuscript met the ICMJE “uniform requirements” for biomedical papers.
Submitted:
26. 3. 2015
Accepted:
10. 6. 2015
Sources
1. Rosen LS. Angiogenesis inhibition in solid tumors. Cancer J 2001; 7 (Suppl 3): S120– S128.
2. Saif MW. Anti‑VEGF agents in metastatic colorectal cancer (mCRC): are they all alike? Cancer Manag Res 2013; 5: 103– 115. doi: 10.2147/ CMAR.S45193.
3. Pircher A, Wellbrock J, Fiedler W et al. New antiangiogenic strategies beyond inhibition of vascular endothelial growth factor with special focus on axon guidance molecules. Oncology 2014; 86(1): 46– 52. doi: 10.1159/ 000356871.
4. Banerjee D, Hernandez SL, Garcia A et al. Notch suppresses angiogenesis and progression of hepatic metastases. Cancer Res 2015; 75(8): 1592– 1602. doi: 10.1158/ 0008‑ 5472.CAN‑ 14‑ 1493.
5. Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti‑VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 2005; 333(2): 328– 335.
6. Vyzula R et al. Modrá kniha České onkologické společnosti. 20. vyd. [citováno 13. ledna 2015]. Dostupné z: http:/ / www.linkos.cz/ informace‑ pro‑praxi/ modra‑ kniha/ .
7. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350(23): 2335– 2342.
8. Avastin.com [homepage on the Internet]. What are the possible side effects of Avastin? [cited 2015 January 13]. Available from: http:/ / www.avastin.com/ patient/ treatment/ possible‑ side‑ effects.
9. Kabbinavar F, Hurwitz H, Fehrenbacher L et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/ leucovorin (LV) with FU/ LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21(1): 60– 65.
10. Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an anti‑vascular endothelial cell growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349: 427– 434.
11. Saltz LB, Clarke S, Díaz‑ Rubio E et al. Bevacizumab in combination with oxaliplatin‑based chemotherapy as first‑line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26(12): 2013– 2019. doi: 10.1200/ JCO.2007.14.9930. Erratum in: J Clin Oncol 2008; 26(18): 3110. J Clin Oncol 2009; 27(4): 653.
12. Emea.europa.eu [homepage on the Internet]. Příloha I: Souhrn údajů o přípravku. [cited 2014 November 24]. Available from: http:/ / www.emea.europa.eu/ docs/ cs_CZ/ document_library/ EPAR_– _Product_Information/ human/ 000582/ WC500029271.pdf.
13. Medicaltribune.cz [homepage on the Internet]. Vavrečka J. Jake farmakoterapeuticke postupy jsou lege artis? Medical Tribune 25/ 2011, 07.11.2011 13:05, [cited 2015 April 9]. Available from: http://www.tribune.cz/clanek/24658-jake-farmakoterapeuticke-postupy-jsou-lege-artis
14. Khorana AA, Streiff MB, Farge D et al. Venous thrombembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action. J Clin Oncol 2009; 27(29): 4919– 4926. doi: 10.1200/ JCO.2009.22.3214.
15. Blom JW, Doggen CJ, Osanto S et al. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005; 293(6): 715– 722.
16. Francis CW. Prevention of venous thromboembolism in hospitalized patients with cancer. J Clin Oncol 2009; 27(29): 4874– 4880. doi: 10.1200/ JCO.2009.22.3644.
17. Daher IN, Yeh ET. Vascular complications of selected cancer therapies. Nat Clin Pract Cardiovasc Med 2008; 5(12): 797– 805. doi: 10.1038/ ncpcardio1375.
18. Byun JY, Mousa SA. Thromboprophylaxis in cancer patients receiving bevacizumab. J Appl Hem 2011; 2(4): 273– 279.
19. Nalluri SR, Chu D, Keresztes R et al. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta‑analysis. JAMA 2008; 300(19): 2277– 2285. doi: 10.1001/ jama.2008.656.
20. Suenaga M, Mizunuma N, Kobayashi K et al. Management of venous thromboembolism in colorectal cancer patients treated with bevacizumab. Med Oncol 2010; 27(3): 807– 814. doi: 10.1007/ s12032‑ 009‑ 9289‑ 6.
21. Hambleton J, Skillings J, Kabbinavar F et al. Safety of low‑dose aspirin (ASA) in a pooled analysis of 3 randomized, controlled trials (RCTs) of bevacizumab (BV) with chemotherapy (CT) in patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol 2005; 23 (Suppl 16): 259, abstr. 3554.
22. Lee AY, Levine MN, Baker RI et al. Low‑ molecular‑ weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349(2): 146– 153.
23. Samama MM, Cohen AT, Darmon JY et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophyliaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 1999; 341(11): 793– 800.
24. Leizorovicz A, Cohen AT, Turpie AG et al. Randomized, placebo‑ controleed trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004; 110(7): 874– 879.
25. Agnelli G, Bergqvist D, Cohen AT et al. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high‑risk abdominal surgery. Br J Surg 2005; 92(10): 1212– 1220.
26. Hambleton J, Novotny WF, Hurwitz H, et al: Bevacizumab does not increase bleeding in patients with metastatic colorectal cancer receiving concurrent anticoagulation. J Clin Oncol 2004; 22 (Suppl 14): 252, abstr. 3528.
27. Leighl NB, Bennouna J, Yi J et al. Bleeding events in bevacizumab‑treated cancer patients who received full‑dose anticoagulation and remained on study. Br J Cancer 2011; 104(3): 413– 418. doi: 10.1038/ sj.bjc.6606074.
Labels
Paediatric clinical oncology Surgery Clinical oncologyArticle was published in
Clinical Oncology
2015 Issue 4
Most read in this issue
- Extraoseus Ewing‘s Sarcoma, Primary Affection of Uterine Cervix – Case Report
- Embryonal Tumors with Multilayer Rosettes – Rare Central Nervous System Tumors in Infants
- Potential of Cell‑free Circulating DNA in Diagnosis of Cancer
- Estimated Glomerular Filtration Rate in Oncology Patients before Cisplatin Chemotherapy